Detalhe da pesquisa
1.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Blood
; 140(17): 1845-1857, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917453
2.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
J Clin Oncol
; 42(15): 1766-1775, 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38471061
3.
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
J Clin Oncol
; 41(26): 4236-4246, 2023 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379495
4.
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
Antimicrob Agents Chemother
; 54(5): 1678-83, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20145081
5.
Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.
Cancer Prev Res (Phila)
; 6(5): 448-54, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23531447